Dr. Flannigan’s research program is focused on evaluating genetic and molecular mechanisms contributing to non-obstructive azoospermia (NOA), using precision single-cell strategies and in vitro methods. During fellowship training, he evaluated the role of microRNA-202-5p in Sertoli Cell Only Syndrome (supported by the AUA Care Foundation) and the roles of Y-Box Binding proteins in Maturation Arrest histologic subtypes. Presently, Dr.Flannigan is continuing his work evaluating the genetic and molecular mechanisms contributing to NOA focusing on techniques that facilitate cell-specific evaluation and functional interactions, with the goal of identifying novel therapeutic targets to treat men with no presently available treatments. Dr. Flannigan is also working to identify the molecular underpinnings underlying Peyronies Disease, with hopes of identifying novel therapeutic strategies. Beyond bench science, Dr. Flannigan is involved in numerous clinical trials and is actively involved in research related to preventative health and health promotion jointly with the Canadian Men’s Health Foundation.